Details for New Drug Application (NDA): 202766
✉ Email this page to a colleague
NDA 202766 describes POLYMYXIN B SULFATE, which is a drug marketed by Adrastea Pharma, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Rising, Xellia Pharms Aps, and Paddock Llc, and is included in eight NDAs. It is available from seven suppliers. Additional details are available on the POLYMYXIN B SULFATE profile page.
The generic ingredient in POLYMYXIN B SULFATE is polymyxin b sulfate. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the polymyxin b sulfate profile page.
The generic ingredient in POLYMYXIN B SULFATE is polymyxin b sulfate. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the polymyxin b sulfate profile page.
Summary for 202766
| Tradename: | POLYMYXIN B SULFATE |
| Applicant: | Xellia Pharms Aps |
| Ingredient: | polymyxin b sulfate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 202766
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| POLYMYXIN B SULFATE | polymyxin b sulfate | INJECTABLE;INJECTION | 202766 | ANDA | Fresenius Kabi USA, LLC | 63323-367 | 63323-367-44 | 10 VIAL, GLASS in 1 CARTON (63323-367-44) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS (63323-367-41) |
| POLYMYXIN B SULFATE | polymyxin b sulfate | INJECTABLE;INJECTION | 202766 | ANDA | Xellia Pharmaceuticals USA LLC | 70594-049 | 70594-049-01 | 1 VIAL, GLASS in 1 CARTON (70594-049-01) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500,000 UNITS BASE/VIAL | ||||
| Approval Date: | Jan 15, 2014 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
